James W. Frederiksen

Medicine · Health Sciences

20h-index2.9kcitations61works3.02yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cardiovascular Function and Risk Factors(9), Heparin-Induced Thrombocytopenia and Thrombosis(8), Advanced biosensing and bioanalysis techniques(6), Cardiac Arrest and Resuscitation(5), Blood Coagulation and Thrombosis Mechanisms(5)

Publications61 total

An Aptamer‐Based EXACT Anticoagulant as a Sustainable, Animal‐Free Alternative to Unfractionated Heparin (Adv. Sci. 4/2026)
Advanced Science·2026Open Access
High-throughput plasma proteomic platforms: Insights from a multi-ethnic Asian cohort
2025Open Access
An Aptamer‐Based EXACT Anticoagulant as a Sustainable, Animal‐Free Alternative to Unfractionated Heparin
Advanced Science·2025· 1 citedOpen Access
Andexanet Alfa–Associated Heparin Resistance in Cardiac Surgery: Mechanism and In Vitro Perspectives
Arteriosclerosis Thrombosis and Vascular Biology·2024· 3 citedOpen Access
Andexanet alfa-associated heparin resistance in cardiac surgery: mechanism and <i>in vitro</i> perspectives
2024· 2 citedOpen Access
Aptameric hirudins as selective and reversible EXosite-ACTive site (EXACT) inhibitors
Nature Communications·2024· 12 citedOpen Access
Applications and future of aptamers that achieve rapid-onset anticoagulation
RNA·2023· 11 citedOpen Access
Combining Heparin and a FX/Xa Aptamer to Reduce Thrombin Generation in Cardiopulmonary Bypass and COVID-19
Nucleic Acid Therapeutics·2022· 6 citedOpen Access
Aptamer-based protein inhibitors
Elsevier eBooks·2022· 1 cited
Contributors
Elsevier eBooks·2022
Aptamer-based factor IXa inhibition preserves hemostasis and prevents thrombosis in a piglet model of ECMO
Molecular Therapy — Nucleic Acids·2021· 14 citedOpen Access
Increased yield of endothelial cells from peripheral blood for cell therapies and tissue engineering
UNC Libraries·2020Open Access
Emerging applications of aptamers for anticoagulation and hemostasis
Current Opinion in Hematology·2018· 37 cited
Combination of aptamer and drug for reversible anticoagulation in cardiopulmonary bypass
Nature Biotechnology·2018· 71 citedOpen Access
DesGla-XaS195A Bound to Aptamer 11F7t
2017
RNA Aptamer Against FXa Synergizes with FXa Catalytic Site Inhibitors to Effectively and Reversibly Anticoagulate Blood in an Ex Vivo Oxygenator Circuit
Blood·2016
Increased Yield of Endothelial Cells from Peripheral Blood for Cell Therapies and Tissue Engineering
Regenerative Medicine·2015· 8 citedOpen Access
Abstract 11685: Early Myocardial Gene Expression Profiling After Deep Hypothermic Circulatory Arrest Reveals Ontogenetic Adaptive Mechanisms Underlying Ischemia-Reperfusion Tolerance in the Swine
Circulation·2014
Probing the Coagulation Pathway with Aptamers Identifies Combinations that Synergistically Inhibit Blood Clot Formation
Chemistry & Biology·2014· 17 citedOpen Access
Abstract 570: Aptamers Against Factor Xa or Thrombin Synergize With Catalytic Site Inhibitors of FXa or Thrombin, Respectively, to Effectively Anticoagulate Blood in an Ex Vivo Oxygenator Circuit
Arteriosclerosis Thrombosis and Vascular Biology·2014
page 1 of 4Next →

Frequent Co-authors

Bruce A. Sullenger(12), Lawrence L. Michaelis(11), Joseph LoCicero(10), Reneé S. Hartz(9), Charlene V. Chabata(6), Haixiang Yu(6), Myron L. Weisfeldt(5), John H. Sanders(4), Ruwan Gunaratne(4), E. A. Beierholm(3), Keith A. Horvath(3), Jens Lohrmann(3), Kristin M. Bompiani(3), Nabil K. Thalji(3), Hugh E. Scully(3), George A. Pitoc(3), James L. Weiss(2), Frank C. P. Yin(2), J J Rubenstein(2), Axel W. Joob(2)